It is made available under a CC-BY 4.0 International license .

Point-of-care prognostication in moderate Covid-19: analytical validation and diagnostic

1	T	IT	LE

3	acc	uracy of a soluble urokinase plasminogen activator receptor (suPAR) rapid test
4		
5	AU	THORS
6	Arj	un Chandna, ^{1,2} Raman Mahajan, ³ Priyanka Gautam, ⁴ Lazaro Mwandigha, ⁵ Sabine Dittrich, ^{2,6,7}
7	Vik	ash Kumar, ³ Jennifer Osborn, ⁶ Pragya Kumar, ⁸ Constantinos Koshiaris, ⁵ George M Varghese, ⁴
8	Yoe	el Lubell , ^{2,9} and Sakib Burza ^{3,10}
9		
10	AF	FILIATIONS
11	1.	Cambodia Oxford Medical Research Unit, Angkor Hospital for Children, Siem Reap,
12		Cambodia
13	2.	Centre for Tropical Medicine & Global Health, University of Oxford, Oxford, UK
14	3.	Médecins Sans Frontières, New Delhi, India

- 15 4. Department of Infectious Diseases, Christian Medical College, Vellore, India
- 16 5. Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK
- 17 6. Foundation for Innovative Diagnostics, Geneva, Switzerland
- 18 7. Deggendorf Institut of Technology, European-Campus Rottal Inn, Pfarrkirchen, Germany
- 19 8. Department of Community & Family Medicine, All India Institute of Medical Sciences,
- 20 Patna, India
- 21 9. Mahidol Oxford Tropical Medicine Research Unit, Mahidol University, Bangkok, Thailand

It is made available under a CC-BY 4.0 International license .

22	10.	Department of Clinica	al Research,	, London Schoo	l of Hygiene &	Tropical	Medicine,	London,
----	-----	-----------------------	--------------	----------------	----------------	----------	-----------	---------

- 23 UK
- 24

25 **CORRESPONDING AUTHOR**

- 26 Dr. Arjun Chandna, Cambodia Oxford Medical Research Unit, Siem Reap, Cambodia
- 27 Tel: +855-85-712-586; Email: arjun@tropmedres.ac; arjunchandna@gmail.com
- 28

29 **KEY WORDS**

- 30 COVID-19; SARS-CoV-2; rapid test; point-of-care; suPAR; triage; low- and middle-income
- 31 country; LMIC
- 32

33 SHORT TITLE

- 34 Rapid suPAR-guided prognostication in Covid-19
- 35
- 36

It is made available under a CC-BY 4.0 International license .

37 ABSTRACT

The soluble urokinase plasminogen activator receptor (suPAR) has been proposed as a
biomarker for the risk stratification of patients presenting with acute infections. However, most
studies evaluating suPAR have used platform-based assays, the diagnostic accuracy of which
may differ from point-of-care tests capable of informing timely patient triage in settings
without established laboratory capacity.

43

Using samples and data collected during a prospective cohort study of 425 patients presenting 44 45 with moderate Covid-19 to two hospitals in India, we evaluated the analytical performance and diagnostic accuracy of a commercially-available rapid diagnostic test (RDT) for suPAR, using an 46 enzyme-linked immunoassay (ELISA) as the reference standard. Although agreement between 47 48 the two tests was limited (bias = -2.46 ng/mL [95% Cl = -2.65 to -2.27 ng/mL]), diagnostic 49 accuracy to predict progression to supplemental oxygen requirement was comparable, whether 50 suPAR was used alone (area under the receiver operating characteristic curve [AUC] of RDT = 51 0.73 [95% CI = 0.68 to 0.79] vs. AUC of ELISA = 0.70 [95% CI = 0.63 to 0.76]; p = 0.12) or as part of a previously published multivariable clinical prediction model (AUC of RDT-based model = 52 53 0.74 [95% CI = 0.66 to 0.83] vs. AUC of ELISA-based model = 0.72 [95% CI = 0.64 to 0.81]; p = 54 0.78). 55 Lack of agreement between the suPAR RDT and ELISA in our cohort warrants further 56

57 investigation and highlights the importance of assessing candidate point-of-care tests to ensure

58 management algorithms reflect the assay that will ultimately be used to inform patient care.

It is made available under a CC-BY 4.0 International license .

59	The availability of a quantitative point-of-care test for suPAR opens the door to suPAR-guided
60	risk stratification of patients with Covid-19 and other acute infections in settings with limited
61	laboratory capacity.
62	
63	
64	INTRODUCTION
65	In busy clinical settings the window for effective triage is short. Biochemical biomarkers
66	included in risk stratification tools require rapid turnaround times. However, studies developing
67	triage tools commonly use laboratory-based platforms to quantify biomarker concentrations,
68	the diagnostic accuracy of which may differ from point-of-care tests required to inform timely
69	management of individual patients in settings with limited laboratory capacity. ¹
70	
71	The soluble version of the urokinase plasminogen activator receptor (suPAR) is upregulated
72	during the host response to infection. ² Measurements of suPAR have been shown to be useful
73	in the diagnosis and prognosis of a wide range of infections and infectious syndromes, ³⁻⁸
74	including SARS-CoV-2. ^{9,10} Recently, our group and others developed clinical prediction models
75	incorporating suPAR for both community- and hospital-based triage of patients with Covid-
76	19. ^{11,12} However, although suPAR is measurable using a commercially-available rapid test, these
77	studies quantified suPAR using laboratory-based immunoassays.
78	
79	We performed an analytical validation of a rapid diagnostic test (RDT) for suPAR using samples
80	from a multi-centre prospective cohort study conducted in India. ¹¹ We evaluated the diagnostic

It is made available under a CC-BY 4.0 International license .

81 accuracy of the RDT by comparing the predictive performance of suPAR quantified using the 82 RDT and an enzyme-linked immunosorbent assay (ELISA). Our hypothesis was that the suPAR RDT might be useful for triage of patients presenting with moderate Covid-19 irrespective of its 83 84 analytical performance when compared with the reference test. 85 86 87 **METHODS** 88 Study population and clinical data collection 89 This is a secondary analysis of data collected during a prospective cohort study conducted at 90 two hospitals in India between October 2020 and July 2021. The study design and setting have been described previously.¹¹ Briefly, consenting consecutive adults (aged \geq 18 years) presenting 91 92 with clinically-suspected SARS-CoV-2 infection of moderate severity (defined as peripheral 93 oxygen saturation (SpO₂) \geq 94% and respiratory rate (RR) \leq 30 breaths per minute (BPM) in the 94 context of systemic symptoms) were recruited. Clinical parameters were measured at 95 enrolment. Admitted participants were followed-up each day until death, discharge or day 14, 96 whichever occurred first. For those not admitted or discharged prior to day 14, follow-up was 97 conducted via telephone on days 7 and 14, with participants who reported worsening and/or 98 persistent symptoms recalled to have their SpO₂ and RR measured. The primary outcome for 99 the original study was development of a supplemental oxygen requirement within 14 days of 100 enrolment, defined as any of: $SpO_2 < 94\%$; RR > 30 BPM; $SpO_2/FiO_2 < 400$; or death. 101

102 Laboratory procedures

It is made available under a CC-BY 4.0 International license .

103	Venous blood samples were collected in ethylenediaminetetraacetic acid (EDTA) tubes at
104	enrolment, centrifuged within four hours, and plasma aliquots stored at \leq -20°C. Frozen plasma
105	aliquots were transported on dry ice and thawed at 2-8 $^\circ$ C overnight prior to analysis. suPAR
106	concentrations were quantified using the suPARnostic ELISA and the suPARnostic Quick Triage
107	test (Virogates, Denmark). The suPARnostic ELISA is a simplified double monoclonal antibody
108	sandwich assay which requires $15\mu L$ of plasma. Samples were run in duplicate and mean
109	concentration reported. The Quick Triage test is a RDT based on lateral flow principles. It
110	requires $10\mu L$ of plasma and has a dynamic range of 2-15 ng/mL. Paired with an automated
111	lateral flow optical reader it has a time-to-result of 20 minutes. Both tests were performed as
112	per the manufacturer's instructions using the same aliquot of thawed plasma, ^{13,14} and the
113	operators who performed both tests were blinded to the results of the other test.
114	
115	Primary and secondary outcomes
116	The primary outcome was the diagnostic accuracy of the RDT (index test) assessed by
117	comparing the predictive performance (area under the receiver operating characteristic curve;
118	AUC) of the RDT to the ELISA (reference standard). The secondary outcome was the analytical
119	performance of the RDT, assessed by quantifying the agreement between the RDT and ELISA.
120	
121	Statistical methods
122	Logistic regression was used to quantify the AUC and compare (DeLong method) the diagnostic
123	45.46
	accuracy of the RDT and ELISA (R package: <i>pROC</i>). ^{15,16} The analytical performance of the RDT

It is made available under a CC-BY 4.0 International license .

125	the RDT and the ELISA (R package: <i>blandr</i>). ^{17,18} Assessment of agreement was limited to
126	samples within the dynamic range (2-15 ng/mL) of the RDT. A sensitivity analysis was conducted
127	where samples quantified on the ELISA but outside the dynamic range of the RDT were set to
128	the limits of quantification of the RDT. All analyses were performed in R, versions 4.0.2 and
129	4.0.3. ¹⁹
130	
131	Sample size
132	For the purposes of an analytical validation, the Clinical and Laboratory Standards Institute
133	(CLSI) recommend a minimum sample size of 100 to evaluate agreement between a candidate
134	and reference test. ²⁰ To maximise precision of the results, we used all available samples from
135	the original study (n = 425).
136	
137	Ethical approvals and reporting
138	This investigator-initiated study was prospectively registered (ClinicalTrials.gov; NCT04441372),
139	with protocol and statistical analysis plan uploaded to the Open Science Framework platform
140	(DOI: 10.17605/OSF.IO/DXQ43). Ethical approval was given by the All India Institute for Medical
141	Sciences Patna Ethics Committee; Christian Medical College Ethics Committee; Oxford Tropical
142	Research Ethics Committee; and Médecins Sans Frontières Ethical Review Board. The study is
143	reported in accordance with the Standards for Reporting Diagnostic accuracy studies (STARD)
144	guidelines (Supplementary Material 1). ²¹
145	

It is made available under a CC-BY 4.0 International license .

147 **RESULTS**

148 Clinical outcomes

- 149 Between 22 October 2020 and 3 July 2021, 426 participants were recruited of whom 425 had
- 150 suPAR concentrations quantified using the RDT and ELISA. Three participants were lost-to-

151 follow-up before day 14, leaving 422 participants available for the primary analysis (Figure 1).

152 Eighty-nine participants developed a supplemental oxygen requirement (89/422; 21.1%).

153

154 FIGURE ONE: Eligibility of samples for inclusion in analytical validation and diagnostic

155 accuracy evaluation.

156

157 Limited agreement between the reference ELISA and candidate RDT for guantification of suPAR 158 Forty-four samples returned values outside the dynamic range of the RDT on either the ELISA 159 and/or RDT, leaving 381 paired samples for assessment of agreement. Median suPAR 160 concentration was higher when quantified by the RDT (Table 1; 6.6 vs. 4.2 ng/mL; p < 0.001). 161 The two tests were correlated (Pearson's correlation = 0.66 [95% CI = 0.60-0.71]; p < 0.001) but 162 there was limited agreement, with the RDT returning higher values than the ELISA on average. A Bland-Altman plot indicated a bias of -2.46 ng/mL (95% CI = -2.65 to -2.27 ng/mL) with upper 163 164 and lower limits of agreement of 1.21 ng/mL (95% CI = 0.89 to 1.54 ng/mL) and -6.13 ng/mL 165 (95% CI = -6.45 to -5.81 ng/mL) respectively (Figure 2). A sensitivity analysis in which samples 166 outside the dynamic range of the RDT were set to the limits of detection of the RDT returned 167 similar results (Supplementary Material 2). Given the disagreement with the reference test we

It is made available under a CC-BY 4.0 International license .

- verified the reproducibility of the RDT results by repeating the measurements of all participants
- at one site (n = 125) using another batch of RDTs (Supplementary Material 3).

170

171 **TABLE 1.** Baseline characteristics of the cohort, stratified by progression to supplemental

172 **oxygen requirement.** *Median values (IQR) are reported for continuous variables.* ^{*}*3 participants*

173 missing information about supplemental oxygen requirement excluded from table but included

174 in assessment of agreement. [†]Wilcoxon rank sum test.

175					
47.0		Overall	Develop	ed oxygen requirer	nent
1/6	Baseline characteristics	(n = 378) [*]	No (n = 297)	Yes (n = 81)	p-value [†]
177	Demographic characteristi	cs			
178	Age (years)	54.0 (42.0, 63.0)	54.0 (42.0, 62.0)	54.0 (42.0, 67.0)	0.70
179	Male sex	261 / 378 (69%)	199 / 333 (67%)	62 / 81 (77%)	0.10
180	suPAR assay				
181	suPAR ELISA (ng/ml)	4.2 (3.2 to 5.6)	4.0 (3.1 to 5.3)	5.2 (3.8 to 6.4)	< 0.001
182	suPAR RDT (ng/ml)	6.6 (5.2 to 8.5)	6.2 (5.0 to 8.3)	8.0 (6.8 to 9.4)	< 0.001

183

FIGURE TWO: Relationship between the suPAR RDT and ELISA. Left panel: Bland-Altman plot indicating agreement between the two tests. Difference between RDT and ELISA measurement in ng/mL plotted on y-axis. Mean of the RDT and ELISA measurement in ng/mL plotted on x-axis. Limits of agreement defined by the concentrations within which 95% of the data fall. Blue line indicates bias, green line indicates upper limit of agreement, red line indicates lower limit of

It is made available under a CC-BY 4.0 International license .

agreement, all with 95% confidence intervals. <u>Right panel</u>: Scatterplot indicating correlation
between the two tests.

191

192 Diagnostic accuracy is maintained when a rapid point-of-care test is used to quantify suPAR

193 concentrations instead of a laboratory-based assay

194 Although agreement between the two tests was limited, we recognised that the RDT might still 195 have utility providing predictive performance did not deteriorate when suPAR concentrations 196 were quantified using the RDT rather than the ELISA. Participants who progressed to develop a 197 supplemental oxygen requirement had higher median baseline suPAR levels, irrespective of the 198 assay used for guantification (Table 1; RDT = 8.0 vs. 6.2 ng/mL, p < 0.001; ELISA = 5.2 vs. 4.0ng/mL, p < 0.001). Diagnostic accuracy of the RDT was comparable to the ELISA (Figure 3; AUC 199 200 of RDT = 0.73 [95% CI = 0.68 to 0.79] vs. AUC of ELISA = 0.70 [95% CI = 0.63 to 0.76]; p = 0.12) 201 for discriminating participants who would progress to require supplemental oxygen. Evaluation 202 of the diagnostic accuracy of the RDT within the framework of our previously published 203 multivariable clinical prediction model confirmed comparable predictive performance of the 204 model whether suPAR was quantified using the RDT or the ELISA (AUC of RDT-based model = 205 0.74 [95% CI = 0.66 to 0.83] vs. AUC of ELISA-based model = 0.72 [95% CI = 0.64 to 0.81]; p = 206 0.78). The weighting (regression coefficient) for suPAR within the model differed depending on 207 which assay was used for quantification (Supplementary Material 4). 208

209 FIGURE THREE: Diagnostic accuracy of suPAR quantified using a point-of-care RDT or

210 **laboratory-based ELISA**. *AUC = area under the receiver operating characteristic curve.*

It is made available under a CC-BY 4.0 International license .

2	1	1
2	Т	т

212

213 **DISCUSSION**

We demonstrate equivalent diagnostic accuracy between an index RDT for suPAR and a laboratory-based ELISA to predict progression to supplemental oxygen requirement amongst patients presenting with moderate Covid-19. Comparable predictive performance of the RDT was achieved despite limited agreement with the reference test and was maintained whether suPAR was used alone or as a constituent parameter in a previously published multivariable

219 clinical prediction model for the triage of patients with moderate Covid-19.¹¹

220

221 Our results illustrate the importance of conducting both analytical and clinical validations of 222 candidate point-of-care tests. The limited agreement between the two suPAR tests indicates 223 that the RDT cannot replace or be used interchangeably with the ELISA. Consequently, results 224 from studies utilising different suPAR assays should not be pooled. If the tests are adopted for 225 routine use, cut-offs associated with particular clinical management decisions (for example, 226 admission or discharge from the emergency department) or weightings within multivariable triage tools (prediction models) should be assay-dependent.^{11,12,22} Similarly, if suPAR 227 228 measurements are used to inform participant recruitment into clinical trials, it is important that eligibility criteria are tailored to the assay used for enrolment.²³ 229 230 231 The lack of agreement between the RDT and ELISA in our cohort is unexpected. The

232 manufacturer reports that suPAR concentrations measured using the RDT should be within

It is made available under a CC-BY 4.0 International license .

233	±10% of measurements made on the ELISA, further underlining the need for context specific
234	evaluation. ^{13,22} The impact of different detection methods for suPAR has been demonstrated, ²⁴
235	however in our study both the ELISA and RDT used the same capture antibodies. Although RDT
236	measurements were made after an additional freeze-thaw cycle, multiple studies have
237	confirmed that suPAR concentrations are stable up to at least five repeated freeze-thaw
238	cycles. ^{25,26} In our cohort, suPAR concentrations quantified using the RDT were higher than
239	anticipated for non-severe patients attending an emergency department. ¹³ It is possible that an
240	unknown underlying population factor may have interfered with the functioning of the RDT
241	assay and this merits further investigation. To our knowledge only one other study has
242	quantified suPAR concentrations using the same RDT in India; 66.3% (126/190) of patients had
243	suPAR concentrations > 5.5 ng/mL, however average concentration was not reported. ²⁷
244	Nevertheless, as our results demonstrate, lack of agreement between inexpensive, quick, and
245	practical RDTs and batched, quality-controlled, laboratory-based assays, does not necessarily
246	preclude clinical utility of an index test on the field.
247	
248	This is the first study evaluating the analytical performance and diagnostic accuracy of a RDT for
249	suPAR, head-to-head against a reference test in resource-constrained setting. The RDTs were
250	performed on frozen plasma by laboratory technicians. If the tests were to inform real-time
251	clinical decisions, fresh plasma would be used and trained laboratory technicians may not be
252	available, especially in contexts with limited laboratory capacity. Future research should extend
253	our results to explore the field-based implementation of the RDT using unfrozen patient
254	samples and evaluate reliability and usability amongst lesser-trained practitioners.

It is made available under a CC-BY 4.0 International license .

2	E	Е
2	Э	Э

256	We demonstrate comparable diagnostic accuracy of a rapid, quantitative, point-of-care test for
257	suPAR to the reference laboratory-based ELISA that was used to develop a previously validated
258	clinical prediction model for the triage of patients presenting with moderate Covid-19. These
259	results are promising and should encourage further exploration of the utility of suPAR-guided
260	risk stratification of patients presenting with Covid-19 and other acute infections in settings
261	with limited laboratory capacity. Lack of agreement between the two tests highlights the
262	importance of undertaking evaluations of point-of-care tests to ensure cut-offs and weightings
263	are adjusted accordingly prior to a diagnostic test being recommended for clinical use.
264	
265	
266	ACKNOWLEDGEMENTS
267	The authors thank Emmanuel Moreau at the Foundation for Innovative New Diagnostics (FIND)
268	for his advice during the conduct of the study.
269	
270	
271	FUNDING
272	The PRIORITISE (Prognostication of Oxygen Requirement in Patients with Non-severe SARS-CoV-
273	2 Infection) study was funded by MSF, India, who maintained a sponsor/investigator role for
274	the study. The Wellcome Trust provides core funding to the Mahidol-Oxford Tropical Medicine
275	Research Unit in Bangkok [220211, 215604/Z/19/Z], which supported the design, monitoring
276	and analysis of the study. The suPAR RDTs were procured by FIND with funding from the

- 277 Australian Goverment. CK is supported by a Wellcome Trust/Royal Society Sir Henry Dale
- 278 Fellowship [211182/Z/18/Z]. For the purpose of open access, the author has applied a CC BY
- 279 public copyright license to any Author Accepted Manuscript version arising from this
- 280 submission.
- 281
- 282

283 **REFERENCES**

- Dittrich S, Tadesse BT, Moussy F, et al. Target Product Profile for a Diagnostic Assay to
 Differentiate between Bacterial and Non-Bacterial Infections and Reduce Antimicrobial
 Overuse in Resource-Limited Settings: An Expert Consensus. *PLoS One* 2016; **11**(8):
 e0161721.
- Donadello K, Scolletta S, Covajes C, Vincent JL. suPAR as a prognostic biomarker in sepsis.
 BMC Med 2012; 10.
- Ni W, Han Y, Zhao J, et al. Serum soluble urokinase-type plasminogen activator receptor as
 a biological marker of bacterial infection in adults: a systematic review and meta-analysis.
 Sci Rep 2016; 6: 39481.
- Wittenhagen P, Kronborg G, Weis N, et al. The plasma level of soluble urokinase receptor is
 elevated in patients with Streptococcus pneumoniae bacteraemia and predicts mortality.
 Clin Microbiol Infect 2004; **10**(5): 409-15.
- 296 5. Rabna P, Andersen A, Wejse C, et al. Utility of the plasma level of suPAR in monitoring risk
 297 of mortality during TB treatment. *PLoS One* 2012; **7**(8): e43933.
- Stefanova V, Ngai M, Weckman AM, et al. suPAR as a Prognostic Marker of Ugandan
 Children at Risk of Severe and Fatal Malaria. *Clin Infect Dis* 2022.
- Luo Q, Ning P, Zheng Y, Shang Y, Zhou B, Gao Z. Serum suPAR and syndecan-4 levels predict
 severity of community-acquired pneumonia: a prospective, multi-centre study. *Crit Care* 2018; 22(1): 15.
- Pregernig A, Muller M, Held U, Beck-Schimmer B. Prediction of mortality in adult patients
 with sepsis using six biomarkers: a systematic review and meta-analysis. *Ann Intensive Care* 2019; 9(1): 125.
- 306 9. Arnold DT, Attwood M, Barratt S, et al. Predicting outcomes of COVID-19 from admission
 307 biomarkers: a prospective UK cohort study. *Emerg Med J* 2021; **38**(7): 543-8.
- Rovina N, Akinosoglou K, Eugen-Olsen J, Hayek S, Reiser J, Giamarellos-Bourboulis EJ.
 Soluble urokinase plasminogen activator receptor (suPAR) as an early predictor of severe respiratory failure in patients with COVID-19 pneumonia. *Crit Care* 2020; **24**(1): 187.
- 11. Chandna A, Mahajan R, Gautam P, et al. Facilitating safe discharge through predicting
 disease progression in moderate COVID-19: a prospective cohort study to develop and
 validate a clinical prediction model in resource-limited settings. *Clin Infect Dis* 2022.

314 12. Chalkias A, Skoulakis A, Papagiannakis N, et al. Circulating suPAR associates with severity 315 and in-hospital progression of COVID-19. Eur J Clin Invest 2022; 52(7): e13794. 316 13. Virogates A/S Denmark. Instructions for use: suPARnostic[®] Quick Triage for aLF Reader. 317 Birkerød, Denmark; 2020. 318 14. Virogates A/S Denmark. Instructions for use: Enzyme immunoassay for quantitative 319 determination of soluble urokinase plasminogen activator receptor in human plasma and 320 serum. Birkerød, Denmark; 2020. 321 15. Robin X, Turck N, Hainard A, et al. pROC: an open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinformatics 2011; 12(77). 322 323 16. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the Areas under Two or More 324 Correlated Receiver Operating Characteristic Curves: A Nonparametric Approach. 325 Biometrics 1988; 44: 837-45. 326 17. Bland M, Altman DG. Statistical methods for assessing agreement between two methods of 327 clinical measurement. Lancet 1986; 327(8476): 307-10. 328 18. Datta D. blandr: a Bland-Altman Method Comparison package for R. 2017. 329 19. R Core Team. R: A language and environment for statistical computing. Vlenna, Austria: R 330 Foundation for Statistical Computing; 2020. 331 20. Clinical and Laboratory Standards Institute. Measurement Procedure Comparison and Bias 332 Estimation Using Patient Samples; Approved Guideline — Third Edition (EP09-A3). 333 Philadelphia, USA, 2013. 334 21. Bossuyt PM, Reitsma JB, Bruns DE, et al. STARD 2015: an updated list of essential items for 335 reporting diagnostic accuracy studies. *BMJ* 2015; **351**: h5527. 336 22. Stauning MA, Altintas I, Kallemose T, et al. Soluble Urokinase Plasminogen Activator 337 Receptor as a Decision Marker for Early Discharge of Patients with COVID-19 Symptoms in 338 the Emergency Department. J Emerg Med 2021; 61(3): 298-313. 339 23. Kyriazopoulou E, Poulakou G, Milionis H, et al. Early treatment of COVID-19 with anakinra 340 guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, 341 randomized controlled phase 3 trial. Nat Med 2021; 27(10): 1752-60. 342 24. Winnicki W, Sunder-Plassmann G, Sengolge G, et al. Diagnostic and Prognostic Value of 343 Soluble Urokinase-type Plasminogen Activator Receptor (suPAR) in Focal Segmental 344 Glomerulosclerosis and Impact of Detection Method. Sci Rep 2019; 9(1): 13783. 345 25. Chew-Harris J, Appleby S, Richards AM, Troughton RW, Pemberton CJ. Analytical, 346 biochemical and clearance considerations of soluble urokinase plasminogen activator 347 receptor (suPAR) in healthy individuals. *Clin Biochem* 2019: 69: 36-44. 348 26. Kofoed K, Schneider UV, Scheel T, Andersen O, Eugen-Olsen J. Development and validation 349 of a multiplex add-on assay for sepsis biomarkers using xMAP technology. *Clin Chem* 2006; 350 **52**(7): 1284-93. 351 27. Kumar P, Kakar A, Gogia A, Waziri N. Evaluation of soluble urokinase-type plasminogen 352 activator receptor (suPAR) quick test for triage in the emergency department. J Family Med 353 *Prim Care* 2019; **8**(12): 3871-5. 354

355 **FIGURE ONE**

Eligibility of samples for inclusion in analytical validation and diagnostic accuracy evaluation. 356



It is made available under a CC-BY 4.0 International license .

359 FIGURE TWO

367 368

Relationship between the suPAR RDT and ELISA. Left panel: Bland-Altman plot indicating
agreement between the two tests. Difference between RDT and ELISA measurement in ng/mL
plotted on y-axis. Mean of the RDT and ELISA measurement in ng/mL plotted on x-axis. Limits of
agreement defined by the concentrations within which 95% of the data fall. Blue line indicates
bias, green line indicates upper limit of agreement, red line indicates lower limit of agreement,
all with 95% confidence intervals. <u>Right panel</u>: Scatterplot indicating correlation between the
two tests.





It is made available under a CC-BY 4.0 International license .

369 **FIGURE THREE**

370 Diagnostic accuracy of suPAR quantified using a point-of-care RDT or laboratory-based ELISA.

- 371 AUC = area under the receiver operating characteristic curve.
- 372





374